Overview

Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy - (FIGHT-202)

Status:
Completed
Trial end date:
2021-09-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is evaluate the efficacy of pemigatinib in subjects with advanced/metastatic or surgically unresectable cholangiocarcinoma with FGFR2 translocation who have failed at least 1 previous treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Incyte Corporation